Skip to Content
Merck

1.08643

SAFC

Triton X-100

EMPROVE® EXPERT Ph Eur

Pharma Manufacturing

Synonym(s):

Octoxynol, (p-tert-Octylphenoxy)polyethoxyethanol, O-[4-(1,1,3,3-Tetramethylbutyl)phenoxy]polyethoxyethanol, Polyethyleneglycol-[4-(1,1,3,3-tetramethylbutyl)phenyl]-ether, t-Octylphenoxypolyethoxyethanol, Polyethylene glycol tert-octylphenyl ether

Sign Into View Organizational & Contract Pricing


About This Item

Linear Formula:
t-Oct-C6H4-(OCH2CH2)xOH, x= 9-10
CAS Number:
Beilstein:
2315025
MDL number:
UNSPSC Code:
12352104

Agency

Ph. Eur.

Quality Level

vapor pressure

<0.01 hPa ( 20 °C)

product line

EMPROVE® EXPERT

form

liquid

potency

1900-5000 mg/kg LD50, oral (Rat)
>3000 mg/kg LD50, skin (Rabbit)

mol wt

micellar avg mol wt 80,000
average mol wt 625

aggregation number

100-155

pH

5.0-8.0 (20 °C, 10 g/L in H2O)

CMC

0.2-0.9 mM (20-25°C)

bp

>200 °C/1013 hPa

transition temp

flash point 251 °C
cloud point 65 °C
pour point ~7 °C

density

1.07 g/cm3 at 20 °C

HLB

13.5

storage temp.

15-25°C

SMILES string

CC(C)(C)CC(C)(C)c1ccc(OCCOCCOCCOCCOCCOCCOCCO)cc1

InChI

1S/C28H50O8/c1-27(2,3)24-28(4,5)25-6-8-26(9-7-25)36-23-22-35-21-20-34-19-18-33-17-16-32-15-14-31-13-12-30-11-10-29/h6-9,29H,10-24H2,1-5H3

InChI key

HNLXNOZHXNSSPN-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Finding the right chemical that matches your pharma and biopharma manufacturing needs as well as regulatory demands can be a complicated challenge. With our application know-how and regulatory expertise, we support you in every step of development, scale-up, and production.As part of our Emprove® Program, our raw materials are offered with extensive documentation facilitating compliance of your pharma and biopharma product, full supply chain transparency and risk mitigation. Our SAFC® portfolio of high-quality products for pharma and biopharma manufacturing withstands strict quality control procedures and is produced according to applicable cGMP guidelines.
Our SAFC® portfolio of high-quality products for biopharmaceutical processing withstands strict quality control procedures and is produced according to MQ-500 requirements as defined by the M-Clarity program.

M-Clarity Program

As part of our EMPROVE® Program, our raw materials are offered with EMPROVE® Dossiers which provide comprehensive, up-to-date documentation to help you navigate regulatory challenges, manage risks, and improve your manufacturing processes.

Our comprehensive portfolio of downstream process chemicals not only provides biopharmaceutical manufacturers with high-quality raw materials for production of classical and novel therapies, but also helps them get to market faster and simplify regulatory challenges. Ranging from non-GMP grades for low-risk application, to IPEC-PQG GMP for higher-risk applications, we have products covering all your manufacturing needs.

Biochem/physiol Actions

Widely used non-ionic surfactant for recovery of membrane components under mild non-denaturing conditions.

Other Notes

Due to its low microbial and endotoxin limits, Triton X-100 Emprove® Expert is suitable for biopharma manufacturing needs.

Legal Information

Emprove is a registered trademark of Merck KGaA, Darmstadt, Germany
SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany
Triton is a trademark of The Dow Chemical Company or an affiliated company of Dow

related product

Product No.
Description
Pricing

Signal Word

Danger

Hazard Statements

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Dam. 1 - Skin Irrit. 2

WGK

WGK 3

Flash Point(F)

closed cup

Flash Point(C)

closed cup


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Btissame El Hassouni et al.
Molecules (Basel, Switzerland), 24(24) (2019-12-11)
Inhibition of ribosome biogenesis has recently emerged as a promising strategy for the treatment of metastatic tumors. The RNA polymerase I inhibitor CX-5461 has shown efficacy in a panel of cancer types and is currently being tested in clinical trials.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service